Cantor Fitzgerald Predicts Vaxcyte FY2025 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Vaxcyte in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will earn ($7.02) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Vaxcyte's current full-year earnings is ($4.14) per share.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) earnings per share.

Other analysts have also issued research reports about the company. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a "buy" rating and a $135.00 price target on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of "Buy" and a consensus target price of $145.71.

Vaxcyte Trading Up 3.8 %

NASDAQ PCVX traded up $3.33 during trading hours on Thursday, reaching $89.97. The company had a trading volume of 1,169,409 shares, compared to its average volume of 1,331,822. The stock has a 50-day moving average of $87.29 and a 200 day moving average of $93.88. Vaxcyte has a 1-year low of $58.10 and a 1-year high of $121.06. The stock has a market capitalization of $11.21 billion, a P/E ratio of -19.56 and a beta of 0.98.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors have recently bought and sold shares of the stock. KBC Group NV increased its position in Vaxcyte by 78.0% in the 4th quarter. KBC Group NV now owns 4,775 shares of the company's stock worth $391,000 after purchasing an additional 2,092 shares during the last quarter. Blue Trust Inc. raised its position in Vaxcyte by 125.1% during the fourth quarter. Blue Trust Inc. now owns 835 shares of the company's stock valued at $68,000 after acquiring an additional 464 shares in the last quarter. Avior Wealth Management LLC lifted its stake in Vaxcyte by 21.1% in the fourth quarter. Avior Wealth Management LLC now owns 6,456 shares of the company's stock valued at $528,000 after acquiring an additional 1,124 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Vaxcyte by 21.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company's stock worth $220,000 after acquiring an additional 475 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Vaxcyte by 15.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 74,907 shares of the company's stock worth $6,132,000 after purchasing an additional 10,243 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Insider Activity at Vaxcyte

In other news, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.82, for a total transaction of $1,602,300.00. Following the completion of the transaction, the chief executive officer now owns 435,219 shares in the company, valued at approximately $46,490,093.58. This represents a 3.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at approximately $21,968,226. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 85,982 shares of company stock worth $8,108,425. 3.10% of the stock is currently owned by company insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.